How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hydroxyethylstarch-130-0-4.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Hydroxyethylstarch 130/0,4 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hydroxyethylstarch 130/0,4 (Hydroxyethylstarch 130/0,4) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Synthetic colloid volume expander. Area: Critical Care / Anesthesia.

marketed Synthetic colloid volume expander Critical Care / Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

Hydroxyethylstarch 130/0,4 (Hydroxyethylstarch 130/0,4) — Rigshospitalet, Denmark. Hydroxyethylstarch (HES) 130/0.4 is a synthetic colloid that expands intravascular volume by increasing plasma oncotic pressure and fluid retention in the bloodstream.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Hydroxyethylstarch 130/0,4 TARGET	Hydroxyethylstarch 130/0,4	Rigshospitalet, Denmark	marketed	Synthetic colloid volume expander
HES 130/0.4 (Voluven)	HES 130/0.4 (Voluven)	The Cleveland Clinic	phase 3	Synthetic colloid volume expander

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Synthetic colloid volume expander class)

Rigshospitalet, Denmark · 1 drug in this class
The Cleveland Clinic · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hydroxyethylstarch 130/0,4 — Competitive Intelligence Brief. https://druglandscape.com/ci/hydroxyethylstarch-130-0-4. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing